[K3] Oncology Pipeline: Shaping 2023 and Beyond
Pricing: Free for Members and Non-Members
This session is supported by an unrestricted educational grant from Coherus Biosciences, Inc.
Course Description
The cancer treatment pipeline has continually expanded over the past decade resulting in record-breaking numbers of approvals in the United States. Global spending on cancer medicine was $185 billion in 2021 and is expected to exceed $300 billion by 2026. Representing over one-third of drugs in the pipeline, oncology treatment continues to evolve and provide innovative treatment options. This session will cover key agents recently approved by the FDA or in late-stage development, focusing on novel mechanisms of action. The potential impact on current standards of care and the clinical and financial implications for payers regarding the emergence of these novel therapies will be discussed.
Target Audience
Pharmacists who practice in managed care settings.
Learning Objectives
At the completion of this activity, participants should be able to:
- Identify recently approved and upcoming approvals of high-impact oncology specialty drugs for solid and hematologic malignancies.
- Differentiate the mechanisms of action, indications, safety, and efficacy of newly approved and emerging oncology specialty medications.
- Assess the impact of new and emerging approvals of oncology specialty medications on cost considerations, contracting, benefit formularies, and other managed care processes.
Faculty
Kaelyn C. Boss, PharmD
Clinical Consultant Pharmacist
ForHealth Consulting
University of Massachusetts Chan Medical School
Bhavesh H. Shah, RPh, BCOP
Chief Pharmacy Officer - Hematology Oncology Pharmacy
Boston Medical Center
Moderator
Matt Mitchell, PharmD, MBA, FAMCP
AVP, Pharmacy Services
SelectHealth
Financial Relationship Disclosures
Faculty/Reviewer/Planner | Reported Relevant Financial Relationships |
Kaelyn C. Boss Faculty | Disclosed no relevant financial relationships. |
Bhavesh H. Shah Faculty | Disclosed no relevant financial relationships. |
Casey Koch Reviewer | Disclosed no relevant financial relationships. |
Jennifer Evans Planner | Disclosed no relevant financial relationships. |
- AMCP Staff have disclosed no relevant financial relationships.
- If applicable, relevant financial relationships have been mitigated and documented.
- Content has undergone a peer review to ensure content validity.
ACPE UAN: 0233-0000-23-067-H01-P
Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: November 15, 2023 • Expiration Date: December 31, 2024
Activity Fee: Free for Members and $30 for Non-Members
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at Nexus 2023. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
Available Credit
- 1.25 ACPEThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
- 1.25 Certificate of Completion
Price
Required Hardware/software
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities